Rheumatoid Arthritis — NZ Condition Guide | KiwiMeds

What is Rheumatoid Arthritis?

Rheumatoid arthritis (RA) is a chronic autoimmune condition where the immune system mistakenly attacks the lining of the joints, causing pain, swelling, stiffness, and potentially permanent joint damage. Unlike osteoarthritis (wear-and-tear arthritis), RA is inflammatory and affects joints symmetrically (both sides of the body). It can also affect other organs including the lungs, heart, and eyes. RA affects around 1–2% of New Zealanders and is 2–3 times more common in women.

Symptoms

RA symptoms include painful, swollen, stiff joints (typically hands, wrists, and feet first), morning stiffness lasting more than 30 minutes, fatigue, and general unwellness. In early RA, symptoms may be mild and non-specific, making diagnosis challenging. Over time, without treatment, joint damage occurs — leading to deformity and disability. Early, aggressive treatment significantly improves long-term outcomes.

Causes and Risk Factors

RA is caused by an abnormal immune response — the exact trigger is unknown. Risk factors include being female (especially 40–60 years old), family history of RA, smoking (a major modifiable risk factor — quit smoking to reduce RA risk and improve treatment response), obesity, and possibly gut microbiome changes.

Diagnosis

RA is diagnosed by a rheumatologist based on clinical examination, blood tests (rheumatoid factor, anti-CCP antibodies — though these are not positive in all cases), and imaging (X-rays, ultrasound, or MRI of joints). Early diagnosis is important — joint damage can begin within months of onset.

Treatment in New Zealand

RA treatment should be started promptly. The cornerstone is disease-modifying antirheumatic drugs (DMARDs) — methotrexate is the standard first-line DMARD. NSAIDs and corticosteroids are used for symptom control and bridging. If methotrexate alone is insufficient, combination DMARDs or biologic therapies are used. Pharmac funds multiple biologics for RA including adalimumab, etanercept, infliximab, abatacept, and tocilizumab for eligible patients. The treat-to-target strategy (aiming for remission or low disease activity) has transformed RA outcomes.

NZ-Specific Information

Arthritis New Zealand (arthritis.org.nz) provides NZ-specific support, self-management programmes, and advocacy. All RA patients should be referred to a rheumatologist for management. Pharmac funds multiple biologic therapies for RA patients with inadequate response to standard DMARDs. Methotrexate is fully funded at the standard $5 prescription charge.

Frequently Asked Questions

Can RA be cured? There is no cure, but with modern treatments many people achieve sustained remission — feeling normal with no active inflammation. Is methotrexate safe? Yes, at the low doses used for RA. Regular blood test monitoring is required. Folic acid supplements are taken with methotrexate to reduce side effects. Can I exercise with RA? Yes — exercise is an important part of RA management, helping maintain joint function and overall health.

Supplements That May Support Management

⚠️ Important: The supplements listed below have varying levels of clinical evidence. They are not a substitute for prescribed medications and should only be considered as adjunctive support under the guidance of a qualified healthcare professional. Always inform your GP or pharmacist before commencing any supplement, as interactions with prescribed medicines are possible.

• Omega-3 Fatty Acids (EPA/DHA) — Meta-analyses demonstrate that omega-3 supplementation (≥2.7 g EPA+DHA/day) meaningfully reduces joint pain, morning stiffness, and tender/swollen joints in rheumatoid arthritis, with some patients achieving reduced NSAID requirements.
• Vitamin D — Vitamin D deficiency is highly prevalent in rheumatoid arthritis and associated with increased disease activity. Supplementation is recommended where deficiency is confirmed and may modulate the autoimmune inflammatory process.
• Boswellia (Boswellia serrata) — Boswellia inhibits 5-lipoxygenase, reducing leukotriene production central to joint inflammation. Doses of 100–400 mg of standardised extract (65% boswellic acids) three times daily have demonstrated clinical benefit in inflammatory arthritis.
• Turmeric/Curcumin — Curcumin inhibits NF-κB, COX-2, and TNF-α pathways involved in joint inflammation. Bioavailability-enhanced formulations at 500–1000 mg/day have shown clinically meaningful reductions in inflammatory markers and joint symptoms.
• Folic Acid (adjunct with methotrexate) — For patients on methotrexate, daily folic acid (400 mcg–1 mg/day on non-methotrexate days) is standard practice to reduce gastrointestinal side effects and mouth sores without compromising efficacy.

Relevant Vaccinations

Individuals living with rheumatoid arthritis may benefit from the following vaccinations. Please discuss your vaccination status with your GP or practice nurse, as eligibility and funding through the New Zealand National Immunisation Schedule may apply.

• Influenza (annual) — People with rheumatoid arthritis on immunosuppressive therapy are at increased risk of influenza complications. Annual vaccination is strongly recommended and funded.
• Pneumococcal — Immunosuppressive DMARD and biologic therapy increases susceptibility to pneumococcal infection. Vaccination is recommended for all people with RA.
• Shingles (Shingrix) — JAK inhibitors and biologics increase the risk of herpes zoster. Shingrix is preferred over the live zoster vaccine (contraindicated with many immunosuppressants). Discuss timing with your rheumatologist.
• COVID-19 — People with RA on immunosuppressive therapy are at increased risk of severe COVID-19. Maintaining COVID-19 vaccination and booster doses is strongly recommended.
• Hepatitis B (before biologic therapy) — Hepatitis B screening is required before commencing certain biologics such as rituximab. Vaccination is recommended for non-immune patients prior to therapy commencement.

Dietary Guidance

Evidence-based dietary modifications play a meaningful role in the management of rheumatoid arthritis. The following foods are generally recommended as part of a balanced, condition-appropriate diet. A referral to a registered dietitian may be beneficial for personalised nutritional planning.

• Mediterranean dietary pattern — The Mediterranean dietary pattern is the most consistently evidenced dietary approach for reducing inflammation and disease activity in rheumatoid arthritis, emphasising anti-inflammatory fats, abundant vegetables, and whole grains.
• Oily fish (salmon, mackerel, sardines) — The primary dietary source of EPA and DHA, which reduce pro-inflammatory eicosanoid production relevant to joint inflammation. Aim for 3+ servings per week.
• Colourful fruits and vegetables — Rich in antioxidants including vitamin C, carotenoids, and polyphenols that reduce oxidative stress and inflammatory signalling. Anthocyanin-rich foods such as berries and cherries are particularly anti-inflammatory.
• Turmeric and ginger in cooking — Curcumin (turmeric) and gingerols (ginger) both inhibit inflammatory pathways relevant to joint inflammation. Regular culinary use provides complementary benefit.
• Limit: red meat, processed meats, refined carbohydrates — Pro-inflammatory dietary patterns high in saturated fat and advanced glycation end-products are associated with higher disease activity scores in rheumatoid arthritis.

Related Conditions & Medications

Related medications: Methotrexate. Related conditions: Osteoporosis.